Blood-based cancer testing is rapidly moving from research labs into everyday clinical practice, offering physicians a less invasive alternative to traditional tissue biopsies for detecting and monitoring tumors. The U.S. liquid biopsy market was valued at USD 1,261.1 million in 2025 and is estimated to grow from USD 1,419.6 million in 2026 to reach USD 3,545.3 million by 2033, registering a compound annual growth rate of 13.79% over the forecast period. This growth is driven by rising demand for non-invasive procedures capable of capturing the complex genomic landscape and intratumoral heterogeneity of cancer, even as tissue biopsy remains the diagnostic standard.
Understanding the Liquid Biopsy Market
The liquid biopsy market comprises products, technologies, and services used to detect and analyze tumor-derived biomarkers from minimally invasive body fluid samples, primarily blood, for disease diagnosis, monitoring, and treatment guidance. The market spans biomarker detection platforms, consumables, instruments, and associated software and services applied across oncology, infectious disease, reproductive health, and other clinical applications, all in support of precision medicine and improved patient management.
Major companies operating in this space include Abbott, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, GRAIL Inc., Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., NeoGenomics Inc., and Thermo Fisher Scientific. In April 2025, Labcorp introduced its Plasma Detect blood test to assess recurrence risk in stage III colon cancer patients, alongside PGDx elio plasma focus Dx, an FDA-authorized pan-solid tumor liquid biopsy test used to identify candidates for targeted therapies.
Key Market Highlights
The ctDNA biomarker segment captured the largest share at 43.45% in 2025, generating USD 547.7 million in revenue. Next-generation sequencing technology accounted for USD 608.0 million in the same year. Kits and reagents held the largest product-type share at 61.43%, valued at USD 774.7 million, while the infectious disease application segment is projected to register the fastest growth rate, at 15.53%, over the forecast period. Hospitals represented the leading end-user category, capturing a 40.13% share and generating USD 506.1 million in 2025.
Precision Oncology Advances Drive Market Growth
Cancer remains the second-leading cause of death in the United States, with more than 1.8 million new diagnoses and over 0.6 million deaths recorded annually. Conventional tissue biopsies require invasive procedures such as surgery or needle extraction, introducing complication risks, particularly for tumors located in hard-to-reach areas. Liquid biopsy offers a non-invasive alternative, analyzing blood samples to detect tumor-derived biomarkers, enabling healthcare providers to detect cancer, guide therapy selection, and monitor treatment response over time. The technology’s expanding applications align closely with precision oncology objectives, supporting data-driven therapy selection and continuous monitoring through tumor DNA analysis.
In May 2026, the FDA approved Guardant360 Liquid CDx, an advanced liquid biopsy panel that expanded its genomic footprint 100-fold compared with its predecessor, integrating genomic and epigenomic data from a single blood draw to enhance detection sensitivity and support better-informed treatment decisions for patients with advanced cancer.
Technical Limitations Constrain Broader Adoption
As a still-emerging technology, liquid biopsy faces limitations that restrict its widespread integration into standard clinical practice. The procedure can miss critical genetic alterations in early-stage disease due to low concentrations of circulating tumor DNA, potentially delaying diagnosis and timely treatment. High costs, limited insurance coverage, and unclear reimbursement pathways further restrict adoption, while the need for rapid sample transport, specialized processing, and advanced sequencing infrastructure limits availability in community or under-resourced healthcare settings. Limited clinician familiarity and lingering patient and regulatory hesitation add further friction to broader adoption.
To address these constraints, market players continue developing advanced liquid biopsy technologies aimed at improving sensitivity and diagnostic accuracy. In March 2026, Volition launched a liquid biopsy technology capable of achieving over 99% purity when isolating circulating tumor DNA from blood samples using its proprietary Capture-Seq platform, combining physical enrichment with bioinformatic analysis to improve detection accuracy. In February 2025, researchers at Oregon Health & Science University developed the PAC-MANN test, designed to enable earlier detection of pancreatic ductal adenocarcinoma using a small blood sample.
AI-Guided Liquid Biopsy Emerges as a Defining Trend
Artificial intelligence is broadening the scope of liquid biopsy by improving diagnostic performance and enabling rapid analysis of hundreds of proteomic signatures associated with cancer-related circulating proteins and nucleic acids. AI adoption supports interpretation of complex, multi-parametric oncology datasets, generating predictive signatures that inform clinical decision-making. Machine learning models applied to circulating tumor DNA sequencing data are enhancing signal-to-noise ratios and enabling earlier detection of cancer recurrence compared with conventional clinical methods.
In January 2026, researchers at Memorial Sloan Kettering Cancer Center developed an AI-powered liquid biopsy that integrates carbon nanotube nanosensors with machine learning, achieving 98% accuracy in detecting and classifying brain tumors from blood samples. In June 2025, Dxcover entered the U.S. liquid biopsy sector to accelerate commercialization of its AI-powered PANAROMIC multiomic cancer detection platform, a non-invasive blood test combining infrared spectroscopy with AI-driven analysis to enable early detection of multiple cancer types.
The U.S. Market Landscape
The presence of a well-established healthcare ecosystem in the U.S., including extensive research laboratories and medical facilities, combined with per capita healthcare spending nearly double the global average, presents substantial growth opportunities for liquid biopsy adoption. Cancer screening plays a critical role in reducing mortality through early tumor detection and removal of precancerous lesions, and according to the National Institutes of Health, nearly 4.75 million deaths have been prevented through screening over the past 45 years.
According to the American Cancer Society, approximately 2.1 million new cancer cases are expected to be diagnosed in the U.S. in 2026, with deaths projected to reach nearly 626,000. Persistent risk factors, including excessive UV exposure, tobacco use, high body mass index, physical inactivity, and poor dietary habits, continue to drive cancer incidence, reinforcing demand for early diagnosis solutions. In February 2026, the U.S. government enacted the Medicare Multi-Cancer Early Detection Screening Coverage Act, allowing Medicare coverage for FDA-approved multi-cancer early detection tests upon CMS determination, a policy shift expected to expand access to advanced cancer screening technologies.
Regulatory Framework
The FDA, through its Center for Devices and Radiological Health and in collaboration with the Oncology Center of Excellence, regulates oncology diagnostic devices to ensure safety, effectiveness, and clinical reliability, while also supporting innovation through approval of companion diagnostics and AI-based diagnostic tools. Additionally, the FDA’s Pre-Market Approval (PMA) framework for Class III medical devices provides guidelines for evaluating safety and effectiveness of devices that support or sustain human life.
Competitive Landscape
The U.S. liquid biopsy market has rapidly transitioned from a niche research concept into a mainstream clinical diagnostic tool, propelled by evolving federal policy aimed at improving cancer outcomes. Companies are prioritizing strategic acquisitions and technical collaborations, supported by continued investment from agencies including the National Institutes of Health and the Department of Health and Human Services.
In November 2025, Inspira Technologies signed a term sheet to acquire advanced liquid biopsy cancer diagnostics technology, securing a USD 15 million investment at a USD 180 million valuation. That same month, Abbott announced its acquisition of Exact Sciences for approximately USD 21 billion, adding key diagnostic products including Cologuard, Oncotype DX, Cancerguard, and Oncodetect to strengthen its cancer detection and monitoring capabilities. Key companies in this market also include Adaptive Biotechnologies, Natera Inc., Naveris, Northstar Liquid Biopsy, and Veracyte Inc.
Market Segmentation Overview
- By Biomarker: ctDNA, CTC, cfDNA (non-tumor), Extracellular Vesicles & Exosomes, Others
- By Technology Platform: NGS, PCR Based (PCR, qPCR, digital PCR), Microarray, Others
- By Product Type: Kits & Reagents (Consumables), Instruments, Software & Services
- By Application: Oncology, Infectious Disease, Reproductive Health, Others
- By End User: Hospitals, Diagnostic & Clinical Laboratories, Reference Laboratories, Others
Outlook for Stakeholders
As AI-guided detection methods mature and reimbursement pathways expand through initiatives like the Medicare MCED Screening Coverage Act, liquid biopsy is positioned to move further into mainstream oncology care. For clinicians, this shift promises earlier, less invasive cancer detection and more precise treatment guidance. For investors and diagnostic developers, the market’s projected 13.79% CAGR through 2033, combined with an active wave of strategic acquisitions among leading players, signals continued opportunity across next-generation genomic profiling, AI-driven diagnostics, and expanded clinical testing capacity.
